The Bivalirudin versus Heparin in non-ST and ST-segment elevation myocardial infarction in patients on modern antiplatelet therapy in SWEDEHEART

Back

ESC Premium Access

The Bivalirudin versus Heparin in non-ST and ST-segment elevation myocardial infarction in patients on modern antiplatelet therapy in SWEDEHEART

Session: Late-Breaking Science in PCI 2

Topic: Thrombosis and platelets

Speaker: Professor D. Erlinge (Lund, SE)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor David Erlinge

Lund University, Lund (Sweden)

11 presentations

0 follower

5 more presentations in this session

Efficacy and Safety of a Pharmaco-Invasive Strategy versus Primary Angioplasty in ST-Elevation Myocardial Infarction: The EARLY-MYO Trial

Speaker: Professor B. HE (Shanghai, CN)

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes - TROPICAL-ACS - Trial

Speaker: Professor D. Sibbing (Munich, DE)

RE-DUAL PCI : Dual Antithrombotic Therapy with Dabigatran After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation

Speaker: Professor C. Cannon (Boston, US)

Have we reached the bottom line in mortality after Acute Myocardial Infarction? Changes over 20 years in patient characteristics, management, and 6-month outcomes in the FAST-MI programme: 1995-2015

Speaker: Professor N. Danchin (Paris, FR)

Improvement in FFR predicts 2 years outcome after PCI. A FAME 2 Sub-Analysis.

Speaker: Doctor S. Fournier (Lausanne, CH)

Access the full session

Late-Breaking Science in PCI 2

Speakers: Professor D. Erlinge, Professor B. HE, Professor D. Sibbing, Professor C. Cannon, Professor N. Danchin...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources